Zetia Franchise
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Multiple combination products based on the same active compound are known as a drug franchise. Franchises exist to give physicians, as well as patients, different treatment choices and to help with issues such as pill burden and compliance. These factors are of particular importance in dyslipidemia as many patients are likely to be taking a variety of medications, requiring various pills and dosing regimens. The Zetia (ezetimibe; Merck & Co) franchise offers combination preparations involving Zetia and the statin drugs Lipitor (atorvastatin calcium; Pfizer/Astellas/Menarini/Almirall) and Zocor (simvastatin; Merck & Co), based on their complementary mechanisms of action.
Despite demonstrating a small but significant improvement in cardiovascular (CV) outcomes in the IMPROVE-IT trial, the US Food and Drug Administration (FDA) rejected Zetia’s label expansion for the reduction of CV risk. This decision followed a negative recommendation from the FDA’s advisory committee, which questioned the robustness of the results and the clinical meaningfulness of the benefit. Recent entry of generic versions of all three drugs in the Zetia franchise is expected to result in the erosion of franchise sales. Zetia’s position is further threatened by the market entry of the proprotein convertase subtilisin/kexin type 9 inhibitors, which have shown superior low-density lipoprotein cholesterol-lowering abilities in Phase III clinical trials.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Zetia franchise : Dyslipidemia
LIST OF FIGURES
11 Figure 1: Zetia franchise for dyslipidemia – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Zetia for dyslipidemia
13 Figure 3: Datamonitor Healthcare’s drug assessment summary of Vytorin for dyslipidemia
14 Figure 4: Datamonitor Healthcare’s drug assessment summary of Liptruzet for dyslipidemia
15 Figure 5: Datamonitor Healthcare’s drug assessment summary of Zetia for dyslipidemia
16 Figure 6: Datamonitor Healthcare’s drug assessment summary of Vytorin for dyslipidemia
17 Figure 7: Datamonitor Healthcare’s drug assessment summary of Liptruzet for dyslipidemia
19 Figure 8: Zetia sales for dyslipidemia across the US, Japan, and five major EU markets, by country, 2017–26
21 Figure 9: Vytorin sales for dyslipidemia across the US, Japan, and five major EU markets, by country, 2017–26
23 Figure 10: Liptruzet sales for dyslipidemia across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Zetia franchise products
6 Table 2: Zetia drug profile
7 Table 3: Vytorin drug profile
7 Table 4: Liptruzet drug profile
9 Table 5: Zetia franchise pivotal trial data in dyslipidemia
20 Table 6: Zetia sales for dyslipidemia across the US, Japan, and five major EU markets, by country ($m), 2017–26
22 Table 7: Vytorin sales for dyslipidemia across the US, Japan, and five major EU markets, by country ($m), 2017–26
24 Table 8: Liptruzet sales for dyslipidemia across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Lipitor 
Sign up to the